The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

This study has been terminated.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Jill Bashutski, University of Michigan
ClinicalTrials.gov Identifier:
NCT01279187
First received: January 18, 2011
Last updated: December 9, 2013
Last verified: December 2013

January 18, 2011
December 9, 2013
February 2011
July 2015   (final data collection date for primary outcome measure)
Bone formation rate [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
To determine the impact of PTH on bone quality and bone turnover in the oral cavity. The primary outcome variable will be bone formation rate.
Same as current
Complete list of historical versions of study NCT01279187 on ClinicalTrials.gov Archive Site
bone turnover [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]
include serum and GCF parameters of bone turnover, cellular parameters of PTH action (i.e. numbers of osteoblasts, osteoclasts, apoptotic osteoblasts) along with derived outcomes such as; the correlation of systemic serum PINP and bone structure and dynamic indices at baseline; changes in systemic PINP as correlated with local bone formation rates in the mandible; and whether numbers of apoptotic osteoblasts correlate with bone formation rates.
Same as current
Not Provided
Not Provided
 
The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone
The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

Good bone healing and bone build-up are necessary for the success of dental implants. Research in animals and humans has shown that a drug, called Forteo, can increase bone build-up and bone strength over time. Forteo has been approved by the Food and Drug Administration (FDA) for use in patients with a condition where bone is broken down and weakened, called osteoporosis. The investigators do not know, however, whether Forteo is effective for use in humans for improving bone healing after implant placement, and whether it will have the same bone-building and bone-strengthening effects as for patients with osteoporosis. This research study is being done to learn what effect 7 weeks of treatment with Forteo will have on bone build-up and strengthening of bone for patients receiving implants.

A single center, placebo-controlled, double blind parallel study of teriparatide use in patients requiring dental implant therapy is planned. Subjects who qualify based on the inclusion/exclusion criteria will be randomly placed into one of two treatment groups, teriparatide (20 μg/day) or placebo control. Both patients and investigators will be blinded. Serum and gingival crevicular fluid (GCF) samples, radiographs, and a tetracycline-labelled bone core will constitute the main data gathered for analysis. After implant surgery, patients will return at 2 weeks for post-operative care and then at 14 weeks for an implant impression and again at 16 weeks to receive the final restoration. Twelve months after implant placement, patients will be seen for a follow-up exam and standardized radiograph to ensure proper healing.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Implant
  • Drug: Teriparatide
    20ug per day,via subcutaneous injection, for 7 weeks
    Other Name: Forteo
  • Drug: Placebo
    20ug per day, self administered injection, for 7 weeks
    Other Name: carrier
  • Experimental: Teriparatide
    demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
    Intervention: Drug: Teriparatide
  • Placebo Comparator: Control
    demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
28
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age range 30-85 yrs
  • Sex: male and female (female subjects must be postmenopausal, surgically sterilized or utilizing birth control or abstinence throughout the period of Teriparatide administration)
  • Subjects must be able and willing to follow study procedures and instructions;
  • Subjects must have read, understood and signed an informed consent form;
  • Subjects must have a need for the replacement of at least one tooth in the mandibular premolar/molar region with at least 12 months since the tooth extraction.
  • Sites must be adaptable for dental implant placement without the necessity for grafting.

Exclusion Criteria:

  • Subjects under 30 years or over 85 years of age,
  • Female subjects who are pregnant, lactating, or female subjects who are of childbearing potential who are not using contraceptives,
  • Subjects with metabolic bone diseases such as Paget's disease, hypercalcemia (mild to moderate hypocalcemia is acceptable for entry into the study), moderate to severe vitamin D3 abnormalities (If vitamin D levels are below 16 ng/ml and patient exhibits interest, dietary supplementation will be suggested and levels re-evaluated after 4 weeks and reconsidered for inclusion at that time), any other metabolic bone diseases including osteoporosis,
  • Subjects with prior radiation therapy, bone metastases or other skeletal malignancy,
  • Subjects on medications that would affect bone metabolism,
  • Subjects with growth hormone deficiency,
  • Subjects with uncontrolled diabetes, sprue, inflammatory bowel disease or other disorders that would affect calcium absorption
  • Subjects that are heavy smokers (> 1 pack/d),
  • Subjects with tetracycline sensitivity or allergy,
  • Subjects on bisphosphonates,
  • Subjects with any form of kidney disease including kidney stones (urolithiasis and nephrolithiasis),
  • Subjects with known allergies to tetracycline and/or demeclocycline,
Both
30 Years to 85 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01279187
HUM00042770
No
Jill Bashutski, University of Michigan
University of Michigan
Eli Lilly and Company
Principal Investigator: Jill Bashutski, DDS, MS Faculty
University of Michigan
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP